NextFin News - Encube Ethicals Pvt., the topical drug specialist backed by Quadria Capital, has appointed investment banks to lead a $400 million initial public offering in Mumbai, marking a decisive pivot after a year of stalled private stake sale negotiations. The company is working with Kotak Mahindra Capital Co. and Goldman Sachs Group Inc. to prepare for a listing that could value the Goa-based manufacturer at approximately $2 billion, according to people familiar with the matter. The move signals a shift in strategy for founder Mehul Shah, who had previously explored a majority stake sale to private equity consortia including Warburg Pincus and Mubadala Investment Co.
The decision to tap the public markets follows a valuation standoff that characterized much of late 2025 and early 2026. While potential suitors were reportedly circling the business with offers in the $1.6 billion range, the promoters held firm on a $2 billion price tag, buoyed by the company’s specialized focus on "topicals"—creams, ointments, and gels—which command higher margins than traditional oral solids. By opting for an IPO, Encube is betting that public market investors will accord it the premium typically reserved for high-growth Contract Development and Manufacturing Organizations (CDMOs) rather than the discounted multiples often applied to generic drugmakers.
Encube’s financial trajectory has been underpinned by a strategic transformation from a pure-play contract manufacturer into a brand owner. The 2021 acquisition of a portfolio of dermatology brands from Sanofi was a watershed moment, providing the company with immediate scale and a direct line to the consumer market. This "hybrid" model—retaining a robust CDMO business while growing a branded portfolio—has made Encube a rare asset in the Indian pharmaceutical landscape. Quadria Capital, which invested in the firm in 2021 at an $800 million valuation, stands to see a significant paper gain, though the private equity firm is expected to retain a portion of its stake to signal confidence to new public shareholders.
The timing of the filing reflects a broader resurgence in the Indian IPO market, which has remained resilient despite global volatility. For U.S. President Trump’s administration, the continued strength of Indian pharma exports remains a point of scrutiny, yet Encube’s heavy reliance on USFDA-approved facilities in Goa positions it as a critical, high-quality link in the global healthcare supply chain. As the "China Plus One" strategy matures, global pharmaceutical majors are increasingly outsourcing complex formulations to Indian specialists who can navigate the rigorous regulatory requirements of the American and European markets.
The success of the offering will likely hinge on Encube’s ability to prove that its margin profile is sustainable as it scales its branded business. While the CDMO segment provides steady, predictable cash flows, the branded side requires heavier marketing spend and faces stiffer competition from established domestic giants like Sun Pharmaceutical Industries and Glenmark. Investors will be looking closely at the utilization rates of its Goa plant, which is one of the largest integrated topical manufacturing facilities in the world. If the $400 million raise proceeds as planned, it will provide the capital necessary to further expand its R&D capabilities and potentially pursue more bolt-on acquisitions in the specialized dermatology space.
Explore more exclusive insights at nextfin.ai.
